Colorectal Cancer | sciencenewsnet.in

New $5.7 Million Grant Aims to Increase Colorectal Cancer Screening, Follow-Up Care in Appalachia

Cancer-control researchers at the University of Kentucky Markey Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) aim to increase colorectal cancer screening and follow-up care among underserved individuals in Appalachia through a $5.7 million grant from the National Cancer Institute.

Announcement

American College of Gastroenterology Announces Winners of Fifth Annual SCOPY Awards

October 28, 2019 sarah Jonas 0 Comments ACG 2019 Annual Scientific Meeting, American College of Gastroenterology Annual Scientific Meeting 2019, Colon Cancer, Colorectal Cancer

American College of Gastroenterology announces 2019 SCOPY Award winners (Service Award for Colorectal Cancer Outreach, Prevention, and Year-Round Excellence) to recognize the achievements of ACG members in their community engagement, education and awareness efforts for colorectal cancer prevention

Research Results

Microbiome Provides New Clues to Determining Development of Colon Cancer

October 4, 2019 sarah Jonas 0 Comments Cancer, Cancer Screening, Colon Cancer, Colorectal Cancer, Gastroenterolgy, GW School of Medicine and Health Sciences, Microbiome, Nutrition

Findings showcasing a connection between bacteria in the microbiome and colon cancer, which may be used to screen younger populations at risk, were published in the journal Gastroenterology by researchers from the George Washington University.

Research Results

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

September 30, 2019 sarah Jonas 0 Comments Colorectal Cancer, ESMO, MD Anderson Cancer Center, NEJM

The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.